IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Eggert Stockfleth	Confirmation No.:	7550
Serial No.:	10/574,422	Art Unit:	1655
Filed:	November 7, 2006	Examiner:	Mi, Qiuwen
Customer No.:	21559		
Title:	THE USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROUS OR PRE-CANCEROUS LESION OF THE SKIN		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO RESTRICTION REQUIREMENT

In reply to the Restriction Requirement that was mailed in connection with the above-captioned case on April 23, 2007, Applicant elects the following species, numbered as indicated in the Office communication:

(1) R1, R2, R5, R6, R7, and R8 are OH; R3 is H; and R4 and R9 are formula (III);

(2) the additive isopropyl myristate;

(3) the carrier ointment;

(4) the anticancer treatment curettage;

(5) the chemotherapy agent 5-fluorouracil;

(6) the radiation X-ray radiation; and

(7) the skin lesion actinic keratosis.

The claims readable on the elected species are claims 1-6 and 8-35.

This election is made without traverse. In the event that a generic claim is allowed, Applicant requests that claims to the remaining species be considered as provided by 37 C.F.R. § 1.141 and MPEP § 809.02(a).

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 23 May 2007

Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045